We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms HER2-targeting ADC

News   Apr 03, 2014

 
Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms HER2-targeting ADC
 
 
Advertisement
 

RELATED ARTICLES

A Mirror-image Peptide Tumor Treatment

News

Scientists have developed a new approach to immunological tumor treatment. Their method is based on the specific blockade of an immune checkpoint by a stable "mirror-image" peptide.

READ MORE

Light-activated Nanoparticles Inhibit Tumor Growth

News

A unique nanoparticle to deliver a localized cancer treatment inhibits tumor growth in mice, according to new research conducted at Penn State University.

READ MORE

Regulatory T Cells Modified by Key Gene To Fine-tune the Immune Response

News

Researchers have discovered genetic “dial” to control regulatory T cells, a finding that could have implications for cancer and autoimmune disease treatment.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE